Denali Therapeutics (DNLI) Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome

Go back to Denali Therapeutics (DNLI) Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome
(NASDAQ: DNLI) Delayed: 53.97 +0.53 (0.99%)
Previous Close $53.44    52 Week High
Open $52.50    52 Week Low
Day High $54.16    P/E N/A 
Day Low $51.41    EPS
Volume 441,459